Cullinan Oncology (CGEM) Investor Presentation - Slideshow

1. CTCAE v5.0. 2. 100 mg patient with Gr3 pneumonitis confounded by recent treatment with CPI and concurrent hydropneumothorax in contralateral lung; 150 mg patient with Gr3 pneumonitis confounded by concurrent pneumocystis infection, had stopped zipalertinib 3 weeks prior to event; 100 mg patient with grade 1 pneumonitis treated with steroids with resolution and continued therapy; 65 mg patient with Gr 2 pneumonitis previously had pneumonitis on osimertinib. 16 Zipalertinib Phase 1/2a and pivotal study des ...